The time to re-enter the RNAi revolution is now,” said Robert Nelsen, the managing director of Arch, which led the Series A funding round for City Therapeutics.
Christine and I are excited to support this fellowship program at UMass Chan and the RNA Therapeutics Institute. The future is brightest when we invest and support our young leaders!
The Cambridge, Massachusetts-based biotech is using what it calls ligand-siRNA conjugates to reach drug targets in the kidney, which historically have been difficult to reach with RNA therapies.